Drug intelligence / Profile preview

BA 0125

Development stage: Unknown
Lead developer: Alsys
Modality: Small Molecules

Overview

BA 0125 is a small-molecule natural product candidate being developed by Alsys for the treatment of plaque psoriasis. It is designed as a multi-target inhibitor that acts on S100 proteins and several key pro-inflammatory cytokines, including interleukin-23 (IL-23), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). By modulating these signaling pathways, BA 0125 aims to reduce the inflammatory skin pathology associated with psoriasis. The drug is currently in the clinical safety stage of development, which corresponds to Phase 1.

Targets

IL-6 (Interleukin 6)S100 (S100 calcium-binding protein)IL-23 (Interleukin-23)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on BA 0125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA 0125.

Explore the full profile